Sakar Healthcare share price
NSE: SAKARPharmaceuticals & BiotechnologySmall Cap
Last close ₹889.80down ₹62.00 (6.51%)
Share price at the NSE close on 23 Oct 2026. Previous close ₹951.80.
52-week range of traded prices to 23 Oct 2026
₹352.00Low, 27 Oct 2025₹1,229.85High, 23 Sep 2026
- Under NSE's long-term additional surveillance, stage I, on the list for 23 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Next results date: the board meets on 23 Oct 2026 to consider: financial results and other business matters.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹1,980 Cr1,357th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 23 Oct 2026
- 46.2
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 23 Oct 2026
- 5.7
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 23 Oct 2026
- 13.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 23 Oct 2026
- 16.6%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026. The filing of 23 Oct 2026
- 0.13
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 7,47,09017.5% delivered
Results
Standalone, as consolidated accounts are on record for only 6 of the last ten years; ₹ crore, the charts by years to March, the table by quarter. No standalone results on record for the year to Mar 2019.Quarterly results
Quarter to Sep 2026, against the quarter beforeFiled 23 Oct
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹87 Crup 19.79%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹11 Crup 9.94%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- 12.9%
Revenue by year
Peak revenue ₹252 Cr, year to Mar 2026
Net profit by year, a loss in red
| ₹ crore | Dec 2024Filed 8 Feb | Mar 2025Filed 15 May | Jun 2025Filed 28 Jul | Sep 2025Filed 7 Nov | Dec 2025Filed 5 Feb | Mar 2026Filed 12 May | Jun 2026Filed 24 Jul | Sep 2026Filed 23 Oct |
|---|---|---|---|---|---|---|---|---|
| Revenue | 43.4 | 50.2 | 52.7 | 57.6 | 70.3 | 71.1 | 73.0 | 87.4 |
| Net profit | 4.5 | 5.8 | 4.7 | 4.5 | 10.2 | 11.0 | 10.3 | 11.3 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | 10.4% | 11.5% | 8.9% | 7.9% | 14.6% | 15.5% | 14.1% | 12.9% |
Standalone. The last eight quarters. The latest is shaded.
Business segments
In the year to Mar 2026 the company reports one business segment, Pharmaceuticals, which carries all its revenue.
Valuation
Today, against the company's own history. Dividend yield is not shown: no dividend in the years on record.PE ratio and valuation history
Price to earningsPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
At or below today's level on 56% of 1,240 trading days over the last 5 years.
LowestHighest
Its median43.8Industry median28.1
Price to bookPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
At or below today's level on 92% of 948 trading days since Oct 2022.
LowestHighest
Its median2.8Industry median2.8
EV to EBITDAEnterprise value to EBITDA. Market cap plus borrowings less cash and bank balances, divided by operating profit before depreciation (revenue less operating expenses, without other income and one-off items) over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly): what the whole business costs against the profit its operations make. Lease liabilities are not counted: the results filings do not state them.22.4
At or below today's level on 71% of 948 trading days since Oct 2022.
LowestHighest
Its median18.4Industry median18.7
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | +135.4% | +71.9% | +37.0% | 0.0% |
| 3 years | +35.4% | +27.6% | +6.1% | 0.0% |
| 5 years | +34.5% | +14.8% | +17.2% | 0.0% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add.
Peers and competitors
Pharmaceuticals, 216 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Sakar Healthcare in market cap.
Where the company sits among the companies nearest its size
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 Beta DrugsBETA | 2,107 | 39.0 | 4.8 | 22.2 | – | – | 16.4% | 14.2% | 0.00% |
 Indoco RemediesINDOCO | 2,091 | 371.3 | 2.2 | 18.7 | +12.1% | – | 0.6% | 1.7% | 0.09% |
 Sai ParenteralsSAIPARENT | 2,040 | – | 4.2 | – | – | – | – | – | 0.00% |
 Syncom Formulations (India)SYNCOMF | 1,992 | 23.3 | 4.8 | 22.6 | +0.4% | +48.6% | 22.6% | 19.5% | 0.47% |
 Panacea BiotecPANACEABIO | 1,908 | – | 2.3 | 852.5 | +10.3% | −162.0% | −0.9% | −3.6% | 0.00% |
 Venus RemediesVENUSREM | 1,877 | 16.2 | 2.8 | 11.1 | +19.9% | +116.3% | 19.0% | 21.1% | 0.71% |
 Windlas BiotechWINDLAS | 1,801 | 27.1 | 3.1 | 17.4 | +18.5% | +2.4% | 12.2% | 12.2% | 0.72% |
 Hester BiosciencesHESTERBIO | 1,750 | 12.8 | 4.9 | 22.3 | +4.1% | +262.2% | 40.4% | 11.7% | 0.53% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Latest announcements
Routine notices left out.Share news and announcements
Oct 2026
22 Oct · Analysts
14 Oct · General Updates
Sep 2026
Sakar Healthcare share price by year
Each calendar year to 2025.Sakar Healthcare share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 409.20 | +38.0% | 426.90 | 211.72 |
| 2024 | 296.45 | −25.9% | 442.05 | 284.85 |
| 2023 | 400.05 | +78.4% | 407.55 | 194.00 |
| 2022 | 224.25 | +37.9% | 286.25 | 106.60 |
| 2021 | 162.65 | +65.5% | 202.70 | 91.10 |
| 2020 | 98.25 | +46.6% | 103.25 | 47.75 |
| 2019 | 67.00 | +12.6% | 69.80 | 45.95 |
| 2018 | 59.50 | −4.0% | 79.90 | 53.00 |
| 2017 | 62.00 | +3.4% | 75.70 | 49.00 |
| 2016 | 59.95 | – | 59.95 | 47.00 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2016 is from its first session, 14 Oct 2016.
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on NSE.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 23 Oct 2026 | 956.00 | 1,019.00 | 855.70 | 889.80 | 926.45 | 7,47,090 | 17.5% |
| 22 Oct 2026 | 904.80 | 955.50 | 872.50 | 951.80 | 925.72 | 1,27,832 | 46.4% |
| 21 Oct 2026 | 927.80 | 988.50 | 875.00 | 904.80 | 920.92 | 2,02,977 | 35.3% |
| 19 Oct 2026 | 952.50 | 968.90 | 915.00 | 923.20 | 938.06 | 66,081 | 48.8% |
| 16 Oct 2026 | 996.00 | 1,010.00 | 952.00 | 961.70 | 981.32 | 60,438 | 46.8% |
| 15 Oct 2026 | 1,012.00 | 1,025.70 | 976.60 | 989.50 | 994.37 | 96,936 | 46.9% |
| 14 Oct 2026 | 961.00 | 1,034.10 | 948.00 | 1,020.80 | 999.60 | 1,89,953 | 39.4% |
| 13 Oct 2026 | 971.10 | 982.70 | 914.10 | 951.60 | 940.78 | 2,45,153 | 46.7% |
| 12 Oct 2026 | 1,023.90 | 1,026.10 | 964.60 | 981.50 | 983.98 | 1,07,905 | 50.5% |
| 9 Oct 2026 | 1,002.00 | 1,030.30 | 941.90 | 1,011.50 | 975.38 | 2,43,394 | 45.0% |
Prices in ₹ per share as traded, not adjusted.
Company details
- Legal name
- Sakar Healthcare Limited
- NSE symbol
- SAKAR
- ISIN
- INE732S01012
- Industry
- Pharmaceuticals & Biotechnology
- Listed
- Oct 2016
- Face value
- ₹10